# Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

> **NCT00129441** · PHASE2 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 16 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Merck L-830982
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00129441
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2011-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129441, "Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00129441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*